CellmAbs is a biotech company focused on the discovery and development of oncology products, aiming to deliver therapeutic and diagnostic solutions to treat patients with cancer. It develops technology that targets a specific subset of biomarkers present on the surface of cancer cells, monoclonal antibodies, and adoptive T-cell therapies as well as diagnostic devices for early detection of cancer. CellmAbs offers glyco-immuno-oncology solutions and personalized medicines.